My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

NuVasive, Inc. - Common Stock (NQ:NUVA)

N/A UNCHANGED

Last Price Updated: 4:00 PM EDT, Aug 31, 2023 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about NuVasive, Inc. - Common Stock

< Previous 1 2 3 Next >

Tilray To Crater Over 30%? Here Are 5 Other Price Target Changes For Friday ↗

September 30, 2022

Barclays cut Tilray Inc (NASDAQ: TLRY) price target from $4.5 to $2. Barclays analyst Gaurav Jain maintained an Underweight rating on the stock. Tilray Brands shares rose 0.3% to $2.87 in pre-market...

Via Benzinga

Twitter, Zoom Video And Some Other Big Stocks Moving Lower On Tuesday ↗

August 23, 2022

GigaCloud Technology Inc. (NASDAQ: GCT) fell 29.9% to $29.01 after declining around 14% on Monday.

Via Benzinga

NuVasive Earnings Perspective: Return On Invested Capital ↗

May 18, 2022

According to Benzinga Pro, during Q1, NuVasive (NASDAQ:NUVA) earned $19.20 million, a 152.27% increase from the preceding quarter. NuVasive's sales decreased to $290.76 million, a 3.75% change since...

Via Benzinga

4 Analysts Have This to Say About NuVasive ↗

May 06, 2022

Analysts have provided the following ratings for NuVasive (NASDAQ:NUVA) within the last quarter:

Via Benzinga

NuVasive: Q1 Earnings Insights ↗

May 04, 2022

NuVasive (NASDAQ:NUVA) reported its Q1 earnings results on Wednesday, May 4, 2022 at 05:10 PM. Here's what investors need to know about the announcement. Earnings NuVasive beat estimated earnings by...

Via Benzinga

Where NuVasive Stands With Analysts ↗

January 07, 2022

NuVasive (NASDAQ:NUVA) has observed the following analyst ratings within th...

Via Benzinga

Earnings Scheduled For July 28, 2021 ↗

July 28, 2021

Companies Reporting Before The Bell • Barclays (NYSE:BCS) is likely to report quarterly earnings at $0.55 per share on revenue of $7.90 billion. • United...

Via Benzinga

Earnings Scheduled For May 5, 2021 ↗

May 05, 2021

Companies Reporting Before The Bell • Monmouth Real Estate (NYSE:MNR) is likely to report earnings for its second quarter. • EyePoint Pharmaceuticals (NASDAQ:EYPT...

Via Benzinga

Week Ahead In Biotech (May 2-8): ChemoCentryx Adcom, Ophthalmology Conference Presentations, Earnings Deluge ↗

May 01, 2021

Biopharma stocks experienced volatility in the week ended April 30, as stocks reacted to earnings, data readouts and a handful of FDA decisions. Earnings prints from big name...

Via Benzinga

Earnings Outlook For NuVasive ↗

May 03, 2022

NuVasive (NASDAQ:NUVA) is set to give its latest quarterly earnings report on Wednesday, 2022-05-04. Here's what investors need to know before the announcement. Analysts estimate that NuVasive will...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For March 28, 2022 ↗

March 28, 2022

Upgrades

Via Benzinga

Health Care Stocks Could Use A Surgical Boom — Will It Happen For Stryker, Boston Scientific, Others? ↗

March 15, 2022

Elective procedures are recovering slowly as Covid cases decline. Will they ever boom?

Via Investor's Business Daily

NuVasive: Q4 Earnings Insights ↗

February 23, 2022

NuVasive (NASDAQ:NUVA) reported its Q4 earnings results on Wednesday, February 23, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings...

Via Benzinga

The Daily Biotech Pulse: Kodiak Sinks On Adverse Study Outcome, Marinus Flags Delay In Clinical Trial, Mainz Biomed Gains On Positive Regulatory Development ↗

February 23, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Kodiak's Wet AMD Treatment KSI-301 Did Not Meet Primary Endpoint In Phase...

Via Benzinga

Why Did BofA Securities Give Globus Medical A Double Upgrade? ↗

December 13, 2021

Enabling tech is likely to continue driving Globus Medical Inc’s (NYSE:

Via Benzinga

NuVasive's Q3 Earnings Hit By COVID-19, Staff Shortage; Cuts FY21 Guidance ↗

November 10, 2021

NuVasive Inc (NASDAQ: NUVA) reported Q3 net sales of $270.8 million, an 8.3% decrease on a reported and constant currency basis, missing the consensus of $291.79...

Via Benzinga

Earnings Scheduled For February 23, 2022 ↗

February 23, 2022

Companies Reporting Before The Bell • Sapiens Intl Corp (NASDAQ:SPNS) is likely to report earnings for its fourth quarter. • Plymouth Industrial REIT (NYSE:PLYM)...

Via Benzinga

The Week Ahead In Biotech (Feb. 20-26): Reata Awaits FDA Decision, Bausch Health, Moderna Lead Earnings News Flow ↗

February 20, 2022

Biotech stock extended lower for a second straight week as risk aversion continued to pressure stocks amid geopolitical tensions and macroeconomic worries. On the regulatory front...

Via Benzinga

NuVasive, Inc (NUVA) Q3 2021 Earnings Call Transcript ↗

November 10, 2021

NUVA earnings call for the period ending September 30, 2021.

Via The Motley Fool

Topics Earnings

Benzinga's Top Ratings Upgrades, Downgrades For December 10, 2021 ↗

December 10, 2021

Upgrades According to JP Morgan, the prior rating for Arconic Corp (NYSE:

Via Benzinga

NuVasive: Q3 Earnings Insights ↗

November 09, 2021

NuVasive (NASDAQ:NUVA) reported its Q3 earnings results on Tuesday, November 9, 2021 at 04:00 PM. Here's what investors need to know about the announcement. Earnings NuVasive...

Via Benzinga

The Daily Biotech Pulse: Double Dose Of Positive Tidings For Merck, Alkermes Slips On Partial Termination Of J&J Licensing Deal, Amgen Migraine Drug Data ↗

November 09, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck Gets Antitrust Nod For Acceleron Deal In Germany, Austria, Announces...

Via Benzinga

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

September 13, 2021

Gainers Itamar Medical (NASDAQ:ITMR) shares moved upwards by 44.37% to $29.8 during Monday's pre-market session. The market value of their outstanding shares is at $...

Via Benzinga

This Revolutionary Medical Device Company Goes to 11 ↗

August 13, 2021

To stand tall against a competitive market, NuVasive depends on a strong spinal platform.

Via The Motley Fool

10 Health Care Stocks Showing Unusual Options Activity In Today's Session ↗

August 02, 2021

This unusual options alert can help traders discover the next big trading opportunities. Traders will search for circumstances when the market estimation of an option diverges...

Via Benzinga

NuVasive, inc (NUVA) Q2 2021 Earnings Call Transcript ↗

July 28, 2021

NUVA earnings call for the period ending June 30, 2021.

Via The Motley Fool

Topics Earnings

FDA Flags Certain Biocompatibility Concerns For NuVasive's Orthopedics' Precice Devices ↗

July 09, 2021

The FDA informed healthcare providers of potential biocompatibility concerns with NuVasive Inc's (NASDAQ:

Via Benzinga

NuVasive Inc (NUVA) Q1 2021 Earnings Call Transcript ↗

May 06, 2021

NUVA earnings call for the period ending March 31, 2021.

Via The Motley Fool

Topics Earnings

The Daily Biotech Pulse: Erytech Jumps On Fast Track Designation, GlaxoSmithKline FDA Nod, Alnylam's Clinical Collaboration, 4 IPOs ↗

July 30, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 29) AbbVie Inc. (NYSE: ABBV)...

Via Benzinga

The Daily Biotech Pulse: Athenex, NeoGenomics And Amryt In M&A Mix, European Nod For Roche's Cancer Immunotherapy, Earnings Deluge Continues ↗

May 05, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 4) AbbVie Inc. (NYSE: ABBV)...

Via Benzinga

< Previous 1 2 3 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.